Yanzhi Hsu

Yanzhi Hsu has over 25 years of work experience in the field of biostatistics. Yanzhi is currently the VP of Biostatistics at TG Therapeutics, Inc. since March 2019. Prior to that, they served as the Sr. Director of Biostatistics at Eli Lilly and Company from October 2014 to March 2019. Yanzhi also worked as the Director of Biostatistics at ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company, from April 2011 to September 2014. Yanzhi Hsu gained experience at Novartis as the Asc Director of Biostatistics from October 2005 to April 2011. Before that, they worked at Purdue Pharma as the Asc Sr. Biostatistician from January 2002 to October 2005. Yanzhi Hsu began their career as a Biostatistician at Columbia University Mailman School of Public Health, where they worked from January 1994 to December 2001.

Yanzhi Hsu holds a Bachelor of Science degree in Mathematics from the University of Science and Technology of China, which they obtained from 1986 to 1991. Yanzhi further pursued their studies in the field of Biostatistics at Columbia University, where they completed their Ph.D. degree. Additionally, there is no specific information available regarding their educational experience at the University of Michigan, apart from their involvement in the field of Mathematics.